APS.TO - Aptose Biosciences Inc.
| Previous Close | 2.87 |
| Open | 2.88 |
| Bid | 2.81 x 0 |
| Ask | 2.83 x 0 |
| Day's Range | 2.81 - 2.95 |
| 52 Week Range | 2.17 - 5.97 |
| Volume | 4,729 |
| Avg. Volume | 43,242 |
| Market Cap | 106.138M |
| Beta (3Y Monthly) | 0.58 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.85 |
| Earnings Date | Nov 12, 2018 - Nov 16, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 9.27 |
- Thomson Reuters StreetEvents•20 hours ago
Edited Transcript of APS.TO earnings conference call or presentation 7-Nov-18 1:00pm GMT
Q3 2018 Aptose Biosciences Inc Earnings Call
- GlobeNewswire•yesterday
Aptose to Participate in Upcoming Investor Conferences, Host Key Opinion Leader Event, and Present Data at the Upcoming ASH Meeting
SAN DIEGO and TORONTO, Nov. 20, 2018 -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated.
- GlobeNewswire•15 days ago
Aptose Reports Results for the Third Quarter Ended September 30, 2018
Conference call is scheduled for tomorrow, Wednesday, November 7th at 8:00 AM ET SAN DIEGO and TORONTO, Nov. 06, 2018 -- Aptose Biosciences Inc. (“Aptose” or the.
- GlobeNewswire•20 days ago
Aptose to Present New CG-806 Data at the 2018 ASH Annual Meeting
SAN DIEGO and TORONTO, Nov. 01, 2018 -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated.
- GlobeNewswire•29 days ago
Aptose to Release Third Quarter Ended September 30, 2018 Financial Results on November 6, 2018
Conference Call to Be Held Wednesday, November 7, 2018 SAN DIEGO and TORONTO, Oct. 23, 2018 -- Aptose Biosciences Inc. (NASDAQ: APTO; TSX: APS), a clinical-stage company.
- ACCESSWIRE•2 months ago
Today's Research Reports on ESSA Pharma, Oncolytics Biotech, Aptose Biosciences and OrganiGram
NEW YORK, NY / ACCESSWIRE / October 5, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register ...
- GlobeNewswire•2 months ago
Aptose Biosciences and CrystalGenomics Announce Issuance of European Patent for CG-806
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), today announced that the European Patent Office (“EPO”) has issued European Patent No. EP2940014B1 for CG-806, a first-in-class, highly potent oral small molecule being developed for acute myeloid leukemia (AML), B cell and other hematologic malignancies. The granted patent claims various compounds, including the CG-806 compound, pharmaceutical compositions comprising the CG-806 compound, and uses for the treatment of various diseases, such as cancer. This European patent will be nationalized in, and cover, approximately forty European countries including the United Kingdom, France, Germany, Italy, Netherlands and Spain.
- GlobeNewswire•2 months ago
Aptose to Present at Upcoming Investor Conferences in October 2018
SAN DIEGO, Calif. and TORONTO, Sept. 25, 2018-- Aptose Biosciences Inc., a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced ...
- ACCESSWIRE•2 months ago
Today's Research Reports on Aralez Pharmaceuticals, OrganiGram Holdings, Oncolytics Biotech and Aptose Biosciences
NEW YORK, NY / ACCESSWIRE / September 10, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register ...
- GlobeNewswire•3 months ago
Aptose to Present at Upcoming Investor Conferences in September 2018
SAN DIEGO and TORONTO, Aug. 29, 2018-- Aptose Biosciences Inc., a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced that ...
- ACCESSWIRE•3 months ago
Today's Research Reports on Emblem, OrganiGram Holdings, Oncolytics Biotech and Aptose Biosciences
NEW YORK, NY / ACCESSWIRE / August 10, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register ...
- Simply Wall St.•3 months ago
Breaking Down Aptose Biosciences Inc’s (TSE:APS) Ownership Structure
In this article, I’m going to take a look at Aptose Biosciences Inc’s (TSE:APS) latest ownership structure, a non-fundamental factor which is important, but remains a less discussed subject amongRead More...
- Baystreet•4 months ago
Stocks in play: Aptose Biosciences Inc
Announced that William G. Rice, Chairman, Ph.D., President and Chief Executive Officer, and Gregory ...
- Zacks•4 months ago
New Strong Sell Stocks for July 27th
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
- Zacks•4 months ago
Why Aptose Biosciences (APTO) Could Be Positioned for a Slump
Aptose Biosciences (APTO) has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions as well.
- ACCESSWIRE•4 months ago
Today's Research Reports on Emblem, OrganiGram, Oncolytics Biotech and Aptose Biosciences
NEW YORK, NY / ACCESSWIRE / July 11, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register ...
